Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on Iron Infusion with Ferric Carboxymaltose for Elderly Patients with Severe Aortic Stenosis and Iron Deficiency Undergoing TAVI

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of an iron infusion treatment in elderly patients who have a condition called Aortic Stenosis and are also experiencing Iron Deficiency. Aortic stenosis is a heart condition where the valve that controls blood flow from the heart to the rest of the body becomes narrowed, making it difficult for the heart to pump blood. Iron deficiency occurs when the body does not have enough iron, which is essential for producing healthy red blood cells. The treatment being tested in this study is called Ferinject, which contains a substance known as Ferric Carboxymaltose. This is a type of iron given through an injection or infusion directly into the bloodstream.

The purpose of the study is to determine if this iron treatment can improve the quality of life and exercise capacity in patients who are undergoing a procedure called Transcatheter Aortic Valve Implantation (TAVI). TAVI is a minimally invasive procedure used to replace the narrowed aortic valve. Participants in the study will receive either the iron treatment or a placebo. Over the course of the study, participants will be monitored for changes in their quality of life, ability to exercise, and cognitive function, which refers to mental processes like thinking and memory.

The study will last for several months, during which participants will undergo various assessments, including questionnaires and a walking test, to evaluate their progress. The main goal is to see if the iron treatment can help improve the overall well-being and physical abilities of those with severe aortic stenosis and iron deficiency. The results will help determine if this treatment could be beneficial for similar patients in the future.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after signing an informed consent form, confirming understanding and agreement to the trial's procedures and objectives.

    Eligibility is confirmed based on criteria such as age (65 years or older), presence of severe aortic stenosis, and iron deficiency.

  2. Step 2

    Initial assessments

    Initial assessments include evaluating quality of life, exercise capacity, and cognitive function.

    Quality of life is assessed using a questionnaire, exercise capacity is measured with a 6-minute walk test, and cognitive function is evaluated through a questionnaire.

  3. Step 3

    Treatment administration

    The treatment involves receiving an intravenous iron infusion using ferric carboxymaltose, known as Ferinject.

    The infusion is administered parenterally, meaning it is given by injection or infusion directly into the bloodstream.

  4. Step 4

    Follow-up assessments

    Follow-up assessments occur at 6 months to evaluate the primary and secondary endpoints.

    Primary endpoints include quality of life and exercise capacity, while secondary endpoints assess cognitive function, NYHA classification, patient global assessment, and other health outcomes.

  5. Step 5

    Completion of the trial

    The trial is estimated to end by December 31, 2028.

    Final assessments and data collection are completed to evaluate the overall impact of the treatment on quality of life and health outcomes.

Who can join the trial?

5 criteria

  • Patient must be **65 years or older**.
  • Patient must have **severe aortic stenosis** and **iron deficiency** and be undergoing a successful **TAVI** procedure. **Aortic stenosis** is a condition where the heart's aortic valve narrows. **Iron deficiency** means having low levels of iron in the body.
  • **Iron deficiency** is defined as having **ferritin** levels less than 100 micrograms per liter (ug/L) or **transferrin saturation** less than 20%. **Ferritin** is a protein that stores iron, and **transferrin saturation** is a measure of how much iron is bound to a protein that carries iron in the blood.
  • Patient must be able to complete assessments for **quality of life**, **exercise capacity**, and **cognitive function**. This includes filling out questionnaires and performing a **6-minute walk test**, which measures how far you can walk in six minutes.
  • Patient must have signed an **Informed Consent** form, which means they agree to participate in the study after being informed about it.

Who cannot join the trial?

4 criteria

  • Patients who do not have severe Aortic Stenosis and Iron Deficiency cannot participate. Aortic Stenosis is a condition where the heart's aortic valve narrows, and Iron Deficiency means having low levels of iron in the body.
  • Patients who are not undergoing TAVI cannot participate. TAVI stands for Transcatheter Aortic Valve Implantation, a procedure to replace the aortic valve.
  • Patients who are outside the specified age range cannot participate. The study includes certain age groups only.
  • Patients who belong to a vulnerable population are not eligible. This means people who might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ferric Carboxymaltose is an intravenous iron treatment used in this trial. It is given to patients who have severe aortic stenosis and iron deficiency. The goal of using this medication is to improve the quality of life and exercise capacity in these patients who are undergoing a procedure called Transcatheter Aortic Valve Implantation (TAVI).

What is already known about the treatment

Ferric Carboxymaltose – This medication is administered intravenously, meaning it is given directly into a vein. It is currently being studied in clinical trials to assess its effectiveness in improving quality of life and exercise capacity in elderly patients with severe aortic stenosis and iron deficiency undergoing transcatheter aortic valve implantation (TAVI). Ferric carboxymaltose is primarily used to treat iron deficiency by replenishing iron stores in the body. At the molecular level, it works by releasing iron, which is then incorporated into hemoglobin and other iron-containing enzymes, essential for oxygen transport and energy production. It is classified as an iron replacement product.

Investigated diseases

  • Aortic Stenosis

    Aortic stenosis is a condition where the aortic valve in the heart becomes narrowed, restricting blood flow from the heart to the rest of the body. This narrowing can lead to increased pressure within the heart, causing the heart muscle to thicken and potentially weaken over time. Symptoms may include chest pain, fatigue, shortness of breath, and fainting, especially during physical activity. As the condition progresses, it can lead to heart failure if the heart cannot pump enough blood to meet the body's needs. The severity of symptoms often correlates with the degree of valve narrowing.

  • Iron Deficiency

    Iron deficiency occurs when the body lacks enough iron to produce adequate levels of hemoglobin, the protein in red blood cells that carries oxygen. This deficiency can lead to anemia, characterized by fatigue, weakness, pale skin, and shortness of breath. Iron deficiency can result from inadequate dietary intake, increased iron needs, or loss of iron through bleeding. Over time, the lack of iron can impair physical and cognitive performance and weaken the immune system. It is a common nutritional deficiency worldwide, affecting various age groups.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-505095-29-03Estimated enrolment378 patientsSponsorErasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.